Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer

[1]  D. Hayes.  Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Steinberg,et al.  Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Siddiqui,et al.  Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer , 2020, Investigative and clinical urology.

[4]  A. Drilon,et al.  MET-dependent solid tumours — molecular diagnosis and targeted therapy , 2020, Nature Reviews Clinical Oncology.

[5]  J. Witjes,et al.  European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. , 2020, European urology.

[6]  T. Kamoto,et al.  Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers , 2020, International journal of molecular sciences.

[7]  E. Giovannetti,et al.  HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers , 2019, Critical reviews in clinical laboratory sciences.

[8]  H. Grossman,et al.  Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer? , 2019, European urology oncology.

[9]  T. Nakazawa,et al.  Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis. , 2018, Lung cancer.

[10]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[11]  S. Shariat,et al.  Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder , 2018, World Journal of Urology.

[12]  Young Hak Kim,et al.  Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer , 2017, Oncotarget.

[13]  T. Klatte,et al.  Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy , 2016, Clinical genitourinary cancer.

[14]  A. Vickers,et al.  Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. , 2015, European urology.

[15]  L. Pavone,et al.  HGF/c-MET Axis in Tumor Microenvironment and Metastasis Formation , 2015, Biomedicines.

[16]  Sanjay G. Patel,et al.  Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. , 2015, European urology.

[17]  R. Thompson,et al.  Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. , 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  M. Babjuk,et al.  Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy. , 2013, European urology.

[19]  A. Kibel.  International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial , 2011 .

[20]  R. Millikan,et al.  Clinical Cancer esearch cer Therapy : Clinical Effectiveness of Off-Protocol Adjuvant Chemotherapy for R ients with Urothelial Carcinoma of the Urinary Bladder , 2010 .

[21]  U. Capitanio,et al.  Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. , 2010, The Journal of urology.

[22]  Y. Toiyama,et al.  Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients , 2009, International journal of cancer.

[23]  H. Kanetake,et al.  Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin. , 2009, Human pathology.

[24]  C. Roehrborn,et al.  Predictive Value of Plasma Hepatocyte Growth Factor/Scatter Factor Levels in Patients with Clinically Localized Prostate Cancer , 2008, Clinical Cancer Research.

[25]  Masayuki Takahashi,et al.  Bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through hepatocyte growth factor. , 2007, Urology.

[26]  Y. Lotan,et al.  Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness , 2007, Modern Pathology.

[27]  Y. Lotan,et al.  Precystectomy nomogram for prediction of advanced bladder cancer stage. , 2006, European urology.

[28]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[29]  Chung-Liang Ho,et al.  Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Kitazawa,et al.  Independent prognostic value of serum hepatocyte growth factor in bladder cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  T. Nakamura,et al.  Hepatocyte growth factor in lung morphogenesis and tumor invasion: role as a mediator in epithelium-mesenchyme and tumor-stroma interactions , 1996, Cancer Chemotherapy and Pharmacology.